TABLE 3

Baseline and follow-up median values of serum insulin-related variables by treatment over time

VariableTime (years)PlaceboMetforminTroglitazoneILSP difference among four treatments (Kruskal-Wallis)Placebo vs. troglitazoneMetformin vs. troglitazoneILS vs. troglitazone
n172164187183
Fasting insulin (pmol/l)01441381321320.58
113211190102<0.01
Δ***<0.01
30-min insulin (pmol/l)05134984984740.72
1522447402408<0.01
Δ**<0.01
Sensitivity [1/fasting insulin 1,000/(pmol/l)]06.947.257.587.580.58
17.589.0211.119.80<0.01
Δ***<0.01
Sensitivity {ISI 10,000/ [(pmol/l) × (mmol/l)]}011.812.012.312.50.64
113.215.419.917.0<0.01
Δ***<0.01
Secretion {CIR (pmol/l)/ [(mmol/l)2]}010.19.059.589.060.19
110.38.4710.158.340.05
Δ0.99
Secretion [IGR (pmol/l)/ (mmol/l)]0116.4102.1108.1101.50.24
1109.191.1103.291.40.03
Δ0.43
  • *

    * P < 0.05 for difference from baseline to 1 year (signed-rank test).

  • P < 0.05 compared with troglitazone (Wilcoxon test, adjusted for multiple comparisons, i.e., unadjusted P < 0.0167). Dash indicates no significant difference; n, number of participants with both baseline and 1-year measurements; Δ, test for difference between baseline and 1 year. Conversion of units: for insulin, 1 μU/ml = 6.0 pmol/l; for glucose, 1 mg/dl = 0.05551 mmol/l.